FGFR2 and cholangiocarcinoma: Moreover, precision medicine with targeted therapy, such as targeting isocitrate dehydrogenase-1 mutations and the fibroblast growth factor receptor-2 fusions, is now being used for biliary tract cancer [45], although this is mainly applicable to intrahepatic CCA and not as commonly for eCCA.